Dr Marlyn Fernandez, MD | |
123 Highland Ave Ste 301, Glen Ridge, NJ 07028-1522 | |
(973) 744-3733 | |
(973) 707-5821 |
Full Name | Dr Marlyn Fernandez |
---|---|
Gender | Female |
Speciality | Endocrinology |
Experience | 18 Years |
Location | 123 Highland Ave Ste 301, Glen Ridge, New Jersey |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1124253752 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | 25MA09223600 (New Jersey) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Hackensackumc Mountainside | Montclair, NJ | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Mpv New Jersey Md Services Pc | 5991097669 | 120 |
News Archive
WaferGen Biosystems, Inc., a leading developer of state-of-the-art genetic analysis systems, today announced that WaferGen scientists will present validation results of the company's SmartChip™ Real-Time PCR System at Cambridge Healthcare Institute's 17th International Molecular Medicine Tri-Conference.
Researchers at the New York University Polytechnic School of Engineering have broken new ground in the development of proteins that form specialized fibers used in medicine and nanotechnology. For as long as scientists have been able to create new proteins that are capable of self-assembling into fibers, their work has taken place on the nanoscale. For the first time, this achievement has been realized on the microscale—a leap of magnitude in size that presents significant new opportunities for using engineered protein fibers.
The yellow fever mosquito (Aedes aegypti) is a main vector of deadly diseases like dengue fever, chikungunya, and the Zika virus, which result in hundreds of thousands of deaths worldwide each year.
Nurse-trainer Helena Cumbelembe Inacio was struggling to teach nurses at the health center here the correct combination of medicines to prevent pregnant women with HIV from passing the infection to their children.
Celator Pharmaceuticals today announced that interim safety and efficacy data from its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy ("7+3") in patients 60-75 years of age with untreated acute myeloid leukemia (AML) were presented at the 51st American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana (ASH Abstract # 1033).
› Verified 8 days ago
Entity Name | Hackensack Meridian Health Medical Group - Specialty Care Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1215989249 PECOS PAC ID: 9133032519 Enrollment ID: O20031111000524 |
News Archive
WaferGen Biosystems, Inc., a leading developer of state-of-the-art genetic analysis systems, today announced that WaferGen scientists will present validation results of the company's SmartChip™ Real-Time PCR System at Cambridge Healthcare Institute's 17th International Molecular Medicine Tri-Conference.
Researchers at the New York University Polytechnic School of Engineering have broken new ground in the development of proteins that form specialized fibers used in medicine and nanotechnology. For as long as scientists have been able to create new proteins that are capable of self-assembling into fibers, their work has taken place on the nanoscale. For the first time, this achievement has been realized on the microscale—a leap of magnitude in size that presents significant new opportunities for using engineered protein fibers.
The yellow fever mosquito (Aedes aegypti) is a main vector of deadly diseases like dengue fever, chikungunya, and the Zika virus, which result in hundreds of thousands of deaths worldwide each year.
Nurse-trainer Helena Cumbelembe Inacio was struggling to teach nurses at the health center here the correct combination of medicines to prevent pregnant women with HIV from passing the infection to their children.
Celator Pharmaceuticals today announced that interim safety and efficacy data from its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy ("7+3") in patients 60-75 years of age with untreated acute myeloid leukemia (AML) were presented at the 51st American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana (ASH Abstract # 1033).
› Verified 8 days ago
Entity Name | Mpv New Jersey Md Services Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1215391271 PECOS PAC ID: 5991097669 Enrollment ID: O20160718000760 |
News Archive
WaferGen Biosystems, Inc., a leading developer of state-of-the-art genetic analysis systems, today announced that WaferGen scientists will present validation results of the company's SmartChip™ Real-Time PCR System at Cambridge Healthcare Institute's 17th International Molecular Medicine Tri-Conference.
Researchers at the New York University Polytechnic School of Engineering have broken new ground in the development of proteins that form specialized fibers used in medicine and nanotechnology. For as long as scientists have been able to create new proteins that are capable of self-assembling into fibers, their work has taken place on the nanoscale. For the first time, this achievement has been realized on the microscale—a leap of magnitude in size that presents significant new opportunities for using engineered protein fibers.
The yellow fever mosquito (Aedes aegypti) is a main vector of deadly diseases like dengue fever, chikungunya, and the Zika virus, which result in hundreds of thousands of deaths worldwide each year.
Nurse-trainer Helena Cumbelembe Inacio was struggling to teach nurses at the health center here the correct combination of medicines to prevent pregnant women with HIV from passing the infection to their children.
Celator Pharmaceuticals today announced that interim safety and efficacy data from its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy ("7+3") in patients 60-75 years of age with untreated acute myeloid leukemia (AML) were presented at the 51st American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana (ASH Abstract # 1033).
› Verified 8 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Marlyn Fernandez, MD Po Box 419430, Boston, MA 02241-9430 Ph: (201) 967-8221 | Dr Marlyn Fernandez, MD 123 Highland Ave Ste 301, Glen Ridge, NJ 07028-1522 Ph: (973) 744-3733 |
News Archive
WaferGen Biosystems, Inc., a leading developer of state-of-the-art genetic analysis systems, today announced that WaferGen scientists will present validation results of the company's SmartChip™ Real-Time PCR System at Cambridge Healthcare Institute's 17th International Molecular Medicine Tri-Conference.
Researchers at the New York University Polytechnic School of Engineering have broken new ground in the development of proteins that form specialized fibers used in medicine and nanotechnology. For as long as scientists have been able to create new proteins that are capable of self-assembling into fibers, their work has taken place on the nanoscale. For the first time, this achievement has been realized on the microscale—a leap of magnitude in size that presents significant new opportunities for using engineered protein fibers.
The yellow fever mosquito (Aedes aegypti) is a main vector of deadly diseases like dengue fever, chikungunya, and the Zika virus, which result in hundreds of thousands of deaths worldwide each year.
Nurse-trainer Helena Cumbelembe Inacio was struggling to teach nurses at the health center here the correct combination of medicines to prevent pregnant women with HIV from passing the infection to their children.
Celator Pharmaceuticals today announced that interim safety and efficacy data from its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy ("7+3") in patients 60-75 years of age with untreated acute myeloid leukemia (AML) were presented at the 51st American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana (ASH Abstract # 1033).
› Verified 8 days ago
Dusan Knezevic, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 123 Highland Ave, Suite 302, Glen Ridge, NJ 07028 Phone: 973-748-9555 Fax: 973-748-2003 | |
Joseph Degregorio, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 946 Bloomfield Avenue, Glen Ridge, NJ 07028 Phone: 973-743-1121 Fax: 973-743-2627 | |
Crystal Tank, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 311 Bay Ave, Mmg Internal Med, Glen Ridge, NJ 07028 Phone: 973-748-9246 Fax: 973-748-8755 | |
Benjamin Herbert Safirstein, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 123 Highland Ave, Suite 101, Glen Ridge, NJ 07028 Phone: 973-744-9125 Fax: 973-744-0280 | |
Mazin Khalid, MD Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 946 Bloomfield Ave, Glen Ridge, NJ 07028 Phone: 973-743-1121 Fax: 973-743-2627 | |
Dr. Paul Woroch, Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 123 Highland Ave, Suite 201, Glen Ridge, NJ 07028 Phone: 973-748-9246 Fax: 973-748-8755 |